Taken together, the data from this study suggest that SGLT1 has clinical utility for DCM diagnosis, and SGLT1 inhibition could attenuate apoptosis, to suppress DCM development via the JNK and p38 pathway, providing a promising treatment for DCM. This evidence concerns the gene MAPK8 and familial dilated cardiomyopathy.